Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

Dr. Kolibaba, Associate Chair, Hematology, US Oncology Research, elaborates on the results of the MAGNIFY study specific to the high risk population in indolent NHL patients

Published: 06 June 2017

Recent Videos: Lymphoma (includes NHL, HL, CNS Lymphoma)

video

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma ...

video

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

Dr. Kahl elaborates on his study evaluating ADCT-402 in diffuse large B-cell lymphoma (DLBCL)

video

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

Dr. Kahl shares information on the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma presented at ASH 2017

video

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

Dr. Kahl offers his opinion on the unmet needs in Hodgkin lymphoma

video

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

Dr. Burke, on whether rituximab is an effective maintenance strategy after 1st line bendamustine-rituximab in previously untreated follicular lymphoma patients

video

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

Dr. Copelan elaborates on how allogeneic transplantation is being optimized for lymphoma and myeloma patients and how it compares with ...

video

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

Dr. Rule tells us about the presentation of the ibrutinib data in relapsed/refractory mantle cell lymphoma (MCL) presented at ASH ...

video

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

Dr. Rule shares his thoughts on the clinical development plan with Imbruvica (ibrutinib) in mantle cell lymphoma (MCL)

video

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

Dr. Hagemeister shares what physicians should know about the development of CAR T-cell therapies in lymphoid malignancies

video

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

Dr. Hagemeister on the safety of CAR T-cell therapies for lymphoma patients and recommendations for managing toxicities associated with these ...

Related Videos

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

video-image

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing

video-image

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

video-image

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

video-image

Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas

video-image

Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients

video-image

Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma

video-image

Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated

video-image

Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial

video-image

Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL

video-image

Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL

video-image

John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma

video-image

John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma

video-image

John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma

video-image

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

video-image

Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms

video-image

Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising

video-image

Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients

video-image

Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients

video-image

Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients

video-image

Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas

video-image

Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial

video-image

John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas

video-image

John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms

video-image

John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas

video-image

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma

video-image

Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL

video-image

Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients

video-image

John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients

video-image

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

video-image

Charles Saunders, MD, considers EHR providers in an era of value-based care

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

video-image

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

video-image

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

video-image

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

video-image

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

video-image

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

video-image

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

video-image

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

video-image

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

video-image

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

video-image

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

video-image

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

video-image

Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information

video-image

Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment

video-image

Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions

video-image

Ira Klein, MD, on what the shift toward oral oncolytics means for the supply chain

video-image

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

video-image

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

video-image

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

video-image

Ira Klein, MD, explains how risk management changes the way we manage supply chain

video-image

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

video-image

Steve D’Amato, R.Ph., talks about data capture and data analytics at New England Cancer Specialists

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

video-image

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

video-image

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

video-image

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

video-image

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

video-image

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

video-image

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

video-image

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

video-image

Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine

video-image

Bobby Green, MD, on leveraging genomic testing into actionable data

video-image

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

video-image

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

video-image

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

video-image

James Hamrick, MD, shares his thoughts on how we are evolving toward a learning health care system

video-image

Debra Patt, MD, on what tele-health brings to cancer care

video-image

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

video-image

Linda Bosserman, MD, explains what MACRA means for oncologists today

video-image

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

video-image

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

video-image

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

video-image

Harlan Levine, MD, tells us about the continuous cycle of learning and improving at City of Hope

video-image

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

video-image

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

video-image

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

video-image

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

video-image

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

video-image

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

video-image

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

video-image

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

video-image

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

video-image

Real-World Evidence Compared to Randomized Clinical Trials

video-image

Real-World Evidence as a Mechanism for Patient-Centric Care

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations

video-image

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

video-image

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients

video-image

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

video-image

David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi

video-image

George Simon, MD, FACP, FCCP, on the Checkmate 032 & CTONG 1104 NSCLC studies presented at ASCO

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

video-image

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

video-image

Christopher Logothetis, MD, offers opinion on the efficacy of the AR-V7 test

video-image

Christopher Logothetis, MD, explains how he identifies the right patients for Zytiga versus Xtandi

video-image

Christopher Logothetis, MD, regarding CHAARTED, STAMPEDE, and LATITUDE data from ASCO 2017

video-image

Christopher Logothetis, MD, speculates on the cost implications of abiraterone

video-image

Christopher Logothetis, MD, on why the results of the LATITUDE study will be practice changing

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab

video-image

Richard Goldberg, MD, FASCO, shares his impression of the adjuvant biliary tract study at ASCO 2017

video-image

Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer

video-image

Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers

video-image

Howard Hochster, MD, regarding the new peri-operative regimen FLOT for gastric cancer

video-image

Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients

video-image

Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017

video-image

Patricia Goldsmith discusses the tools available for cancer patients on their journey

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Nancy Dawson, MD, compares the side effect profiles of abiraterone and chemotherapy

video-image

Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated

video-image

Nancy Dawson, MD, regarding the STAMPEDE study presented at ASCO 2017

video-image

Nancy Dawson, MD, shares her impressions of the LATITUDE study

video-image

Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers

video-image

Barbara Burtness, MD, considers whether H&N patients should be routinely tested for PD-L1

video-image

Barbara Burtness, MD, discusses immunotherapies and treatment of head and neck cancers

video-image

Barbara Burtness, MD, shares her thoughts on the results of the LUX head and neck 2 study

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Thaddeus Beck, MD, FACP, on how Watson for Clinical Trials Matching can increase practice efficiency

video-image

Thaddeus Beck, MD, FACP, explains how Watson for Clinical Trials Matching operates

video-image

Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

video-image

Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, considers the relevance of testing for PD-L1

video-image

Jack West, MD, discusses possible immunotherapy combination treatments in the near future

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 test

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, considers data from CHAARTED, STAMPEDE, and LATTITUDE

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on the practice-changing results of the LATITUDE study

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017

video-image

Jeff Sharman, MD, comments on emerging trends in CLL management

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Mohammad Jahanzeb, MD, FACP, comments on the differences between CDK 4/6 inhibitors

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017

video-image

Leonard Saltz, MD, shares thoughts on how to control rising drug prices without impacting value

video-image

Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

video-image

Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer

video-image

Philip Philip, MD, shares his impression of the capcitabine data in biliary cancers

video-image

Philip Philip, MD, reflects on the impact of PEGPH20 in met pancreatic cancer

video-image

Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Daniel Petrylak, MD, on treating bladder cancer patients progressing on checkpoint inhibitors

video-image

Daniel Petrylak, MD, discusses the role of checkpoint inhibition therapy in urothelial carcinoma

video-image

Daniel Petrylak, MD, on prostate cancer guidelines and the results of the LATITUDE study

video-image

Andrew Pecora, MD, FACP, CPE, shares how COTA and IBM Watson are working together

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, on establishing a more informatics enabled oncology practice

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Debra Patt, MD, MPH, MBA, comments on how she sees the new administration addressing drug costs

video-image

Debra Patt, MD, MPH, MBA, offers opinion on incorporating liquid biopsy into patient management

video-image

Debra Patt, MD, MPH, MBA, on the repercussions if utilization management isn’t used properly

video-image

Debra Patt, MD, MPH, MBA, explains the concept and importance of utilization management

video-image

Andrew Norden, MD, speculates on the future of Watson for oncology

video-image

Andrew Norden, MD, on how physicians can take advantage of Watson’s expanding library of tumor types

video-image

Andrew Norden, MD, describes the clinical utility of Watson for oncology

video-image

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

video-image

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

video-image

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

video-image

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

video-image

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

video-image

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

video-image

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

video-image

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

video-image

Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment

video-image

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Nevena Damjanov, MD, comments on identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on the Phase 3 Checkpoint 459 trial studying nivolumab in HCC

video-image

Nevena Damjanov, MD, shares her impressions of lenvatinib data in 1st line uHCC presented at ASCO

video-image

Lyudmila Bazhenova, MD, on the progress being made towards successfully sequencing ALK inhibitors

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Lyudmila Bazhenova, MD, on differentiating between ALK inhibitors

video-image

Lyudmila Bazhenova, MD, speaks to the reliability and accuracy of ALK biomarkers

video-image

Aref Al-Kali, MD, on how hematologists will adopt midostaurin for FLT3+ AML patients

video-image

Aref Al-Kali, MD, on the data coming out of ASCO 2017 regarding FLT3 mutant AML patients

video-image

Aref Al-Kali, MD, offers perspective on treating elderly AML patients

video-image

Nevena Damjanov, MD, discusses new agents being studied for treatment of advanced HCC

video-image

Andrew Norden, MD, on how Watson for Clinical Trial Matching (CTM) operates

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation